BioNTech's Overbought Ascent: A Leadership Handover, a Rival's Tailwind, and a Seoul Deadline

Despite 76% revenue drop, BioNTech shares surge on mRNA cancer vaccine optimism, cash reserves, and pipeline progress ahead of key lung cancer data.

There's a peculiar arithmetic at work in BioNTech's share price right now: revenue down 76 percent year on year, a widened net loss, a slashed full-year forecast — and yet the stock keeps climbing. The Mainz-based biotech closed Friday at €99.80, up 5.1 percent on the day, leaving it just 5.7 percent shy of its 52-week high of €105.80 touched back in January. The rally has been relentless enough that the 14-day relative strength index now sits at 78.3, a reading that screams overbought to any technician worth their salt.

What makes the advance all the more striking is that the latest leg higher was triggered not by BioNTech's own news flow, but by a competitor's. When Moderna and Merck unveiled Phase 3 wins for an mRNA cancer vaccine in mid-August, BioNTech shares jumped roughly 22 percent in a single session — despite no company-specific announcement that day. The market simply extrapolated the rival's success onto BioNTech's comparable pipeline, and the stock proceeded to tack on 24 percent over seven consecutive sessions. It was a sympathy rally in the purest sense: a repricing of an entire drug class rather than a verdict on any single balance sheet.

The numbers themselves tell a more complicated story. BioNTech's second-quarter revenue came in at €105.6 million, down from €260.8 million in the same period a year earlier, as pandemic-era vaccine sales continue their structural decline. Management has trimmed full-year guidance to €1.6–1.9 billion. Yet the market's response to the earnings release was telling: the stock has risen 26.3 percent since that report, with investors choosing to focus on the underlying substance rather than the headline miss. That substance includes a war chest of €16.6 billion in cash, 14 registration-enabling oncology studies in progress, six pivotal trials launched this year, and a share buyback program of up to $1 billion running through May 2027.

The leadership transition adds another layer of complexity. Founder Ugur Sahin is handing the CEO reins to Guido Oelkers, with the changeover slated for completion by February 1, 2027. Since that succession was formally announced roughly three weeks ago, the stock has gained 27.1 percent — a vote of confidence in the strategic pivot from pandemic vaccine maker to diversified oncology and biopharma platform by 2030. But transitions carry execution risk, and this one lands at a delicate moment in the clinical calendar.

That calendar converges on Seoul. At the World Conference on Lung Cancer, running September 12–15, BioNTech will present first-ever global data on the combination of Pumitamig (BNT327) and the antibody-drug conjugate Elfetabart Drozuntecan, alongside updated survival figures from the Phase 3 PRESERVE-003 trial. With 16 ongoing lung cancer studies — five of them in Phase 3 — the presentation carries outsized weight. The oral readout on September 15 could either validate the recent euphoria or trigger a classic sell-the-news reaction if the updated Gotistobart survival data underwhelm.

Institutional positioning suggests the smart money is not uniformly convinced. FMR increased its stake by 32.6 percent in the second quarter, while Flossbach von Storch trimmed meaningfully and Capital International Investors exited entirely. CFO Sierk Poetting has sold roughly $5.5 million worth of shares over the past six months, with no insider purchases to offset the selling. None of that is necessarily a red flag, but it does indicate that not everyone inside or outside the company shares the market's current enthusiasm.

The technical backdrop offers some guideposts. The stock remains above its 50-day moving average of €81.36, and a sustained break above the January high of €105.80 would open the path toward the analyst consensus target of $121.75 — roughly 4.5 percent above current levels. Should the overbought RSI instead roll over, the 100-day average at €81.26 would be the first line of defense. With annualized volatility at 65 percent, the tape is primed for sharp moves in either direction.

From its 52-week low of €68.35, the stock has climbed 46 percent in a matter of months — a run built largely on expectation rather than delivered results. Seoul will provide the first substantive test of whether that advance is justified. Until then, BioNTech remains a stock trading on promise, and promise, as any biotech investor knows, is a fragile foundation.